ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FUM Futura Medical Plc

36.80
2.80 (8.24%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.80 8.24% 36.80 36.60 37.30 37.30 35.00 35.00 753,383 16:35:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -5.85M -0.0194 -18.81 109.76M
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 34p. Over the last year, Futura Medical shares have traded in a share price range of 24.10p to 67.00p.

Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £109.76 million. Futura Medical has a price to earnings ratio (PE ratio) of -18.81.

Futura Medical Share Discussion Threads

Showing 17351 to 17358 of 21500 messages
Chat Pages: Latest  704  703  702  701  700  699  698  697  696  695  694  693  Older
DateSubjectAuthorDiscuss
08/3/2023
22:15
The Netherlands, wasn't that where Blue Diamond 'came and went'?
glavey
08/3/2023
21:31
Hark at LiarBO accusing someone of copy/pasting! Hahahahahahaha!
petroc
08/3/2023
21:30
The multi-ID stock basher (aka LiamBooth, Leveraged, Citygirl, sbgae, LBO8 et al) is making contradictory claims to the results found in two clinical tests and a home use trial. The vast majority of users confirmed that Eroxon works. LiarBO can't show a single piece of evidence that shows otherwise, which is why he has to use spurious and unrelated links in an attempt to tar Eroxon.
petroc
08/3/2023
17:50
Hark at LiarBO accusing someone of copy/pasting! Hahahahahahaha!
petroc
08/3/2023
16:48
All Futura have done with MED3000 is open the door for Reckitt to sell similar lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn't inform consumers that MED3000 itself has no proven effect in ED beyond a placebo. As it has no proven efficacy in an adequate placebo controlled study or even against any standard cooling lubricant/arousal gels in an ED study.https://neo.life/2021/10/the-promise-of-pills-that-do-nothing/'You are the active ingredient'Even the analysis on market forecasts knows Reckitt who is the market leader in lubricants will be only one to gain from marketing lubricants as placebo treatments for Erectile Dysfunctionhttps://www.globenewswire.com/en/news-release/2022/03/17/2405009/28124/en/Global-Personal-Lubricant-Market-Outlook-Forecast-Report-2022-2027-Featuring-Prominent-Vendors-LifeStyles-Church-Dwight-Karex-Berhad-Reckitt-Benckiser-Group-BioFilm.htmlReckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.KEY GROWTH FACTORSIncreasing prevalence of erectile dysfunction9 Market Growth Enablers9.1 Increasing Prevalence of Erectile Dysfunction
lbo
08/3/2023
14:15
BTW, for anyone interested in proper chat about Eroxon, head on over to LSE. They're currently discussing the availability of Eroxon in Europe. No negativity, no back biting, and most importantly, no LiarBO bashing the stock with lies and misinformation! LSE wisely took the decision to ban the lying manipulator over a year ago.
petroc
08/3/2023
14:02
The HCP website that was advertised by Petroc says 'when assessed against internationally accepted criteria for clinical effectiveness (Rosen and Araujo) the efficacy of Eroxon exceeded the minimal clinically important difference' And the HCP Brochure on the same website references the study 'Minimal clinically Important Difference Rosen et al 2011'But its now clear from that exact study that the MCID criteria were estimated based on regular adequately controlled and blinded oral ED studies.The Rosen study also clearly states in its limitations the results have not been replicated in 'non pharmacologic studies'So they are not internationally accepted criteria for 'non pharmacologi studies'or medical device gels which are known to have much higher placebo effect then oral pharmacologic placebos. In one study it was 3 times higher.So now its been shown the MCID is inappropriately being used in HCP marketing to make a indirect cross comparison to non regular inadequately blinded medical device gel studies.https://pubmed.ncbi.nlm.nih.gov/21855209/MCIDs were estimated using data from 17 randomized, double-blind, placebo-controlled, parallel-group clinical trials of the phosphodiesterase type 5 inhibitorlimitationsCurrent analyses were based on 17 clinical trials of tadalafil. Results need to be replicated in studies using other PDE5-Is or in nonpharmacologic intervention studies.
lbo
08/3/2023
13:57
As usual with the multi-ID ramper he cannot substantiate any of false and misleading claims. Like all his posts not all the relevant information is being published on a UK website and only biased information is being disclosed on the website as its known that Med3000 is not a ‘regular’ oral placebo! It is a medical device placebo gel that is being massaged in! Which are known to have higher placebo effects. Yet this is not being adequately disclosed by the rampers

˜some forms of bias, such as publication bias, should be considered as fraud’


petroc - 23 Feb 2023 - 21:53:12 - 16545 of 16566






Bias and Fraud

There are numerous biases in medical research that render evidence from such research systematically misleading. Some of these biases are exacerbated by conflicts of interest, including fantastic financial incentives. The most important biases in medical research include confirmation bias, design bias, analysis bias, and publication bias. Arguably, some forms of bias, such as publication bias, should be considered as fraud. The pervasiveness of bias in medical research justifies one of the premises of the master argument for medical nihilism. Medical research is malleable due to the many biases, and such malleability allows for the production of evidence that suggests medical interventions are effective, whether or not they are in fact effective.

lbo
Chat Pages: Latest  704  703  702  701  700  699  698  697  696  695  694  693  Older

Your Recent History

Delayed Upgrade Clock